ClinicalTrials.gg
Active, not recruitingNCT04654468COMMODORE 3Updated Nov 9, 2026Results posted

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition

A Phase 3 interventional study of Crovalimab in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Hoffmann-La Roche. Active, not recruiting at 5 sites in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Nov 9, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies in Hemoglobinuria, Paroxysmal with a site in China — 21 open to participants now, 29 under way, 11 of them phase 3. Hemoglobinuria, Paroxysmal · China.

Enrollment
17th of 47
51 · median 40
Started
2021
with 3 others
Phase 3
17 of 51
7 open now
Primary completion
2022-02
later than 0 of 28 live
Registered
6th of 51
by date
Lead sponsor
2 of 51
Hoffmann-La Roche

Among the 51 studies in Hemoglobinuria, Paroxysmal with a site in China, this one is the 17th largest by enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2021, is one of 17 in phase 3, reaches primary completion later than 0 of the 28 other live ones, and was the 6th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

21 of the 51 studies in Hemoglobinuria, Paroxysmal with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hemoglobinuria, Paroxysmal with a site in China, or all of them as a file.
02

Study summary

This study will enroll participants aged 12 years or older with a body weight ≥ 40 kilograms (kg) diagnosed with PNH who have not been previously treated with complement inhibitor therapy. Approximately 50 participants will be treated with Crovalimab for at least 24 weeks.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight ≥ 40 kg at screening
  • Willingness and ability to comply with all study visits and procedures
  • Documented diagnosis of PNH, confirmed by high sensitivity flow cytometry
  • LDH Levels ≥ 2x the at screening
  • Participants who have at least four transfusions during 12 months prior to screening (documented in the medical record)
  • Presence of one or more of the PNH-related signs or symptoms within 3 months of screening
  • Vaccination against Neisseria meningitidis serotypes A, C, W, and Y \< 3 years prior to initiation of study treatment (Day 1)
  • Vaccination against Haemophilius influenzae type B and Streptococcus pneumonia according to national vaccination recommendations
  • For participants receiving other therapies (e.g., , ): stable dose for ≥ 28 days prior to screening and up to the first drug administration
  • Adequate hepatic and renal function
  • Women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use during the treatment period and for 46 weeks (approximately 10.5 months) after the final dose of crovalimab
  • count ≥30,000 per cubic millimeter (mm\^3) at screening
  • > 500/microlitres (μl) at screening

Exclusion criteria

Exclusion Criteria:

  • Current or previous treatment with a complement inhibitor
  • History of bone marrow transplantation
  • History of Neisseria meningitidis infection within 6 months prior to screening and up to first drug administration
  • Known or suspected immune or hereditary complement deficiency
  • Known infection with cluster of differentiation 4 (CD4) count \< 200 cells/µl within 24 weeks prior to screening
  • Infection requiring hospitalization or treatment with IV antibiotics within 28 days prior to screening and up to the first drug administration, or oral antibiotics within 14 days prior to screening and up to the first drug administration
  • Active systemic bacterial, viral, or fungal infection within 14 days before first drug administration
  • Presence of fever (≥ 38˚C) within 7 days before the first drug administration
  • Splenectomy \< 6 months before screening
  • History of within 5 years prior to screening and up to the first drug administration
  • Pregnant or intending to become pregnant during the study or within 46 weeks (10.5 months) after the final dose of study treatment
  • Participation in another interventional treatment study with an agent or use of any experimental therapy within 28 days of screening or within 5 half-lives of that investigational product, whichever is greater
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Crovalimab

    Participants will receive a loading series of crovalimab comprised of an intravenous (IV) dose on Day 1, followed by weekly crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.

    Drug: Crovalimab

Interventions

  • Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight between 40 and 100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100 kg) or 1020 mg SC (for participants with body weight ≥ 100 kg). Dosing schedule will be as described above.

06

What researchers measure

Primary outcomes

  1. Mean Percentage of Participants With Hemolysis Control

    A Generalized Estimating Equation (GEE) was used to estimate the population-average percentage of the participants with hemolysis control (measured by lactate dehydrogenase (LDH) ≤1.5 x upper limit of normal (ULN)) from Week 5 to Week 25 taking account of the intra-patient and inter-patient correlation between LDH control statuses across visits. The dependent variable was the binary indicator for hemolysis control. Independent variables are categorical effects of visits, continuous baseline LDH.

    Time frame: From Week 5 up to Week 25

  2. Difference in Percentage of Participants With Transfusion Avoidance (TA) From Baseline Through Week 25 and Within 24 Weeks Prior to Screening

    TA was defined as participants who were packed red blood cell (pRBC) transfusion-free and did not require transfusion per protocol-specified guidelines. TA within 24 weeks prior to screening was based on the pRBC transfusion history in the medical records. Reported in this outcome measure is the difference in the percentage of participants between "baseline through Week 25" and "within 24 weeks prior to screening". 95% Confidence Interval (CI) for the difference between the percentage of participants with transfusion avoidance between Pre-screening and Post-baseline is calculated using the Newcombe method. Screening= Day -28 to Day -1 and Baseline= Day 1.

    Time frame: 24 Weeks Prior to Screening, Baseline to Week 25

Secondary outcomes

  1. Percentage of Participants With Breakthrough Hemolysis (BTH)

    BTH was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath \[dyspnea\], anemia \[hemoglobin \< 10 grams per deciliter (g/dL)\], major adverse vascular event \[MAVE, including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2xULN after a prior LDH reduction to ≤1.5xULN from the start of study treatment. As pre-specified in the SAP participants withdrawing before Week 25 were deemed to have experienced a BTH event. Percentages have been rounded off to the first decimal point.

    Time frame: Baseline, Week 25

  2. Percentage of Participants With Stabilized Hemoglobin

    Stabilized hemoglobin was defined as avoidance of a ≥2 g/dL decrease in hemoglobin level from baseline, in the absence of transfusion. As pre-specified in the SAP participants withdrawing before Week 25 were deemed to not have hemoglobin stabilization.

    Time frame: Baseline, Week 25

  3. Change From Baseline in Fatigue in Adults Aged >=18 Years

    Fatigue was assessed using functional assessment of chronic illness therapy-fatigue (FACIT-F) scale. FACIT-F is a self-assessment questionnaire with a 7-day recall period and 13 items evaluating fatigue and its impact on daily life activities. Items are scored on a response scale that ranges from 0 ("not at all") to 4 ("very much so"). Relevant items are reverse scored, and all the items are summed to create a total score range from 0 to 52, with 0 being the worst possible score and 52 being the best possible score. A higher score indicates low fatigue severity. A positive mean change indicates improvement. FACIT-F was assessed in adult participants only. FACIT-F assessment was unintentionally missed in the Schedule of Activities (SoA) table, which site used to guide the assessments at each timepoint. Therefore, data were not collected at Week 25.

    Time frame: Baseline, Week 2, Week 5, Week 9, Week 17, Week 25

  4. Percentage of Participants With Adverse Events (AEs)

    Time frame: Up to 7 years

  5. Percentage of Participants With Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity, and Infections (Including Meningococcal Meningitis)

    Time frame: Up to 7 years

  6. Percentage of Participants With Adverse Events (AEs) Leading to Study Drug Discontinuation

    Time frame: Up to 7 years

  7. Trough Serum Concentration of Crovalimab Over Time

    Time frame: Up to 7 years

  8. Serum Concentrations of Crovalimab

    Time frame: Up to 7 years

  9. Percentage of Participants With Anti-Drug Antibodies (ADAs) to Crovalimab

    Time frame: Up to 7 years

  10. Terminal Complement Activity as Measured by Liposome Immunoassay (LIA)

    Time frame: Up to 7 years

  11. Change Over Time in Total and Free C5 Concentration

    Time frame: Up to 7 years

  12. Observed Value in Absolute Reticulocyte Count

    Time frame: Up to 7 years

  13. Observed Value in Free Hemoglobin

    Time frame: Up to 7 years

  14. Observed Value in Haptoglobin

    Time frame: Up to 7 years

  15. Percent Change From Baseline in Absolute Reticulocyte Count

    Time frame: Baseline, Week 25

  16. Percent Change From Baseline in Free Hemoglobin

    Time frame: Baseline, Week 25

  17. Percent Change From Baseline in Haptoglobin

    Time frame: Baseline, Week 25

07

Results

Posted Jun 5, 2023

Participant flow

Participants took part in the study at 5 investigative sites in China.

Participant flow — Overall Study
MilestoneCrovalimab
Started51
Completed0
Not completed51
Withdrew: Death1
Withdrew: Ongoing in the study50

Outcome measures

PrimaryMean Percentage of Participants With Hemolysis Control

A Generalized Estimating Equation (GEE) was used to estimate the population-average percentage of the participants with hemolysis control (measured by lactate dehydrogenase (LDH) ≤1.5 x upper limit of normal (ULN)) from Week 5 to Week 25 taking account of the intra-patient and inter-patient correlation between LDH control statuses across visits. The dependent variable was the binary indicator for hemolysis control. Independent variables are categorical effects of visits, continuous baseline LDH.

Time frame:
From Week 5 up to Week 25
Reported as:
Least squares mean · mean percentage of participants
Mean Percentage of Participants With Hemolysis Control
mean percentage of participantsCrovalimab
Mean Percentage of Participants With Hemolysis Control78.66 (67.78 to 86.59)
PrimaryDifference in Percentage of Participants With Transfusion Avoidance (TA) From Baseline Through Week 25 and Within 24 Weeks Prior to Screening

TA was defined as participants who were packed red blood cell (pRBC) transfusion-free and did not require transfusion per protocol-specified guidelines. TA within 24 weeks prior to screening was based on the pRBC transfusion history in the medical records. Reported in this outcome measure is the difference in the percentage of participants between "baseline through Week 25" and "within 24 weeks prior to screening". 95% Confidence Interval (CI) for the difference between the percentage of participants with transfusion avoidance between Pre-screening and Post-baseline is calculated using the Newcombe method. Screening= Day -28 to Day -1 and Baseline= Day 1.

Time frame:
24 Weeks Prior to Screening, Baseline to Week 25
Reported as:
Number · percentage of participants
Difference in Percentage of Participants With Transfusion Avoidance (TA) From Baseline Through Week 25 and Within 24 Weeks Prior to Screening
percentage of participantsCrovalimab
Difference in Percentage of Participants With Transfusion Avoidance (TA) From Baseline Through Week 25 and Within 24 Weeks Prior to Screening50.98 (34.30 to 65.05)
Statistical analysis
  • Crovalimab · Paired McNemar · p = <.0001
SecondaryPercentage of Participants With Breakthrough Hemolysis (BTH)

BTH was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath \[dyspnea\], anemia \[hemoglobin \< 10 grams per deciliter (g/dL)\], major adverse vascular event \[MAVE, including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2xULN after a prior LDH reduction to ≤1.5xULN from the start of study treatment. As pre-specified in the SAP participants withdrawing before Week 25 were deemed to have experienced a BTH event. Percentages have been rounded off to the first decimal point.

Time frame:
Baseline, Week 25
Reported as:
Number · percentage of participants
Percentage of Participants With Breakthrough Hemolysis (BTH)
percentage of participantsCrovalimab
Percentage of Participants With Breakthrough Hemolysis (BTH)3.9 (0.68 to 14.59)
SecondaryPercentage of Participants With Stabilized Hemoglobin

Stabilized hemoglobin was defined as avoidance of a ≥2 g/dL decrease in hemoglobin level from baseline, in the absence of transfusion. As pre-specified in the SAP participants withdrawing before Week 25 were deemed to not have hemoglobin stabilization.

Time frame:
Baseline, Week 25
Reported as:
Number · percentage of participants
Percentage of Participants With Stabilized Hemoglobin
percentage of participantsCrovalimab
Percentage of Participants With Stabilized Hemoglobin51.0 (36.77 to 65.05)
SecondaryChange From Baseline in Fatigue in Adults Aged >=18 Years

Fatigue was assessed using functional assessment of chronic illness therapy-fatigue (FACIT-F) scale. FACIT-F is a self-assessment questionnaire with a 7-day recall period and 13 items evaluating fatigue and its impact on daily life activities. Items are scored on a response scale that ranges from 0 ("not at all") to 4 ("very much so"). Relevant items are reverse scored, and all the items are summed to create a total score range from 0 to 52, with 0 being the worst possible score and 52 being the best possible score. A higher score indicates low fatigue severity. A positive mean change indicates improvement. FACIT-F was assessed in adult participants only. FACIT-F assessment was unintentionally missed in the Schedule of Activities (SoA) table, which site used to guide the assessments at each timepoint. Therefore, data were not collected at Week 25.

Time frame:
Baseline, Week 2, Week 5, Week 9, Week 17, Week 25
Reported as:
Mean · score on a scale
Change From Baseline in Fatigue in Adults Aged >=18 Years
score on a scaleCrovalimab
Baseline31.77 ± 8.53
Change from Baseline at Week 26.67 ± 8.02
Change from Baseline at Week 58.08 ± 9.28
Change from Baseline at Week 98.15 ± 10.61
Change from Baseline at Week 178.77 ± 9.63
SecondaryPercentage of Participants With Adverse Events (AEs)
Time frame:
Up to 7 years

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity, and Infections (Including Meningococcal Meningitis)
Time frame:
Up to 7 years

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Adverse Events (AEs) Leading to Study Drug Discontinuation
Time frame:
Up to 7 years

Results for this outcome have not been posted.

SecondaryTrough Serum Concentration of Crovalimab Over Time
Time frame:
Up to 7 years

Results for this outcome have not been posted.

SecondarySerum Concentrations of Crovalimab
Time frame:
Up to 7 years

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Anti-Drug Antibodies (ADAs) to Crovalimab
Time frame:
Up to 7 years

Results for this outcome have not been posted.

SecondaryTerminal Complement Activity as Measured by Liposome Immunoassay (LIA)
Time frame:
Up to 7 years

Results for this outcome have not been posted.

SecondaryChange Over Time in Total and Free C5 Concentration
Time frame:
Up to 7 years

Results for this outcome have not been posted.

SecondaryObserved Value in Absolute Reticulocyte Count
Time frame:
Up to 7 years

Results for this outcome have not been posted.

SecondaryObserved Value in Free Hemoglobin
Time frame:
Up to 7 years

Results for this outcome have not been posted.

SecondaryObserved Value in Haptoglobin
Time frame:
Up to 7 years

Results for this outcome have not been posted.

SecondaryPercent Change From Baseline in Absolute Reticulocyte Count
Time frame:
Baseline, Week 25
Reported as:
Mean · percent change
Percent Change From Baseline in Absolute Reticulocyte Count
percent changeCrovalimab
Percent Change From Baseline in Absolute Reticulocyte Count40.9411 ± 66.0292
SecondaryPercent Change From Baseline in Free Hemoglobin
Time frame:
Baseline, Week 25
Reported as:
Mean · percent change
Percent Change From Baseline in Free Hemoglobin
percent changeCrovalimab
Percent Change From Baseline in Free Hemoglobin-45.6180 ± 51.8421
SecondaryPercent Change From Baseline in Haptoglobin
Time frame:
Baseline, Week 25
Reported as:
Mean · percent change
Percent Change From Baseline in Haptoglobin
percent changeCrovalimab
Percent Change From Baseline in Haptoglobin295.1351 ± 1735.4180

Adverse events

Collected over From enrollment until primary completion date cutoff (up to approximately 25 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CROVALIMAB1/51 (2%)4/51 (7.8%)46/51 (90.2%)
Most frequent serious events
Most frequent serious events
EventCROVALIMAB
ThrombocytopeniaBlood and lymphatic system disorders1/51
Abdominal wall massGastrointestinal disorders1/51
Bile duct stoneHepatobiliary disorders1/51
BacteraemiaInfections and infestations1/51
Subdural haematomaInjury, poisoning and procedural complications1/51
Platelet count decreasedInvestigations1/51
Most frequent other events
Showing 10 of 19
Most frequent other events
EventCROVALIMAB
Upper respiratory tract infectionInfections and infestations24/51
Bilirubin conjugated increasedInvestigations15/51
Neutrophil count decreasedInvestigations13/51
Blood bilirubin unconjugated increasedInvestigations12/51
White blood cell count decreasedInvestigations12/51
Alanine aminotransferase increasedInvestigations11/51
Blood alkaline phosphatase increasedInvestigations9/51
Blood bilirubin increasedInvestigations9/51
Alpha hydroxybutyrate dehydrogenase increasedInvestigations8/51
Lymphocyte count decreasedInvestigations8/51

Baseline characteristics

Safety population included all enrolled participants who received at least one dose of crovalimab.

Age, Continuous
Age, Continuous(Years)Crovalimab
Mean33.0 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Crovalimab
Female29
Male22
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Crovalimab
Hispanic or Latino0
Not Hispanic or Latino51
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Crovalimab
American Indian or Alaska Native0
Asian51
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

5 sites
09

References and documents

Publications

  • Roth A, Fu R, He G, Alzahrani H, Chou SC, Hicheri Y, Kazmierczak M, Recova VL, Uchiyama M, Vladareanu AM, Beveridge L, Buatois S, Buri M, Compagno N, Shi D, Balachandran N, Sreckovic S, Scheinberg P. Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies. Eur J Haematol. 2025 Feb;114(2):373-382. doi: 10.1111/ejh.14339. Epub 2024 Nov 13. PubMed 39535306 ↗
  • Liu H, Xia L, Weng J, Zhang F, He C, Gao S, Jia J, Chang AC, Lundberg P, Shi J, Sima CS, Sostelly A, Sreckovic S, Xiao Z, Zhang Z, Fu R. Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study. Am J Hematol. 2023 Sep;98(9):1407-1414. doi: 10.1002/ajh.26998. Epub 2023 Jul 8. PubMed 37421604 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Feb 2022, 10 months.

Results were first posted in Jun 2023, 1 year 3 months after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 10 months is below that.

Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2020
First posted
Dec 4, 2020
StartActual
Mar 17, 2021
Primary completionActual
Feb 10, 2022
CompletionEst.
Jan 15, 2027
Results first posted
Jun 5, 2023
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology · Wuhan, China
Show 1 removed
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology · Wuhan, China
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    1 site added, 1 site removed
    Show site
    • Union Hospital Tongji Medical College Huazhong University of Science and Technology · Wuhan, China
    Show 1 removed
    • Union Hospital Tongji Medical College Huazhong University of Science and Technology · Wuhan, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04654468
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 4, 2020
Start date
Mar 17, 2021
Primary completion
Feb 10, 2022
Completion
Jan 15, 2027 (estimated)
Results posted
Jun 5, 2023
Last update
Nov 9, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crovalimab

Start the discussion